The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
|Videos|June 29, 2017
Dr. Stratigos on the Prevention of Melanoma
Author(s)Alexander J. Stratigos, MD
Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.
Advertisement
Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.
Primary prevention is an approach that aims to reduce the exposure of UV radiation on human skin. The primary goals are to reduce the exposure through the use of sunscreen and protective clothing, explains Stratigos.
There is also prevention that aims to protect vulnerable populations such as children or outdoor workers. According to Stratigos, it is important for physicians to understand the early clues of skin cancer to better educate their patients on the importance of prevention.
<<<
Advertisement
Related to this article
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma
5